Innoviva, Inc.
Innoviva, Inc. (INVA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INVA · as of Jun 8, 2026
Key Statistics
Explore Innoviva, Inc. Data
inva stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 50.0%
The INVA analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $40.00, representing +79.13% upside from the current price of $22.33.
Competitors & Peers
inva competitorsINVA
ATAI
CVAC
DNTH
ELVN
IMTXStock Performance
Full HistoryAbout Innoviva, Inc.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily co…
what is innoviva, inc. · inva stock overview · innoviva, inc. company profile · who is innoviva, inc. ceo · inva NASDAQ · innoviva, inc. headquarters · innoviva, inc. business segments
About Stock Overview & Key Data
Innoviva, Inc. (INVA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 5, 2004. As of the latest trading session, INVA stock price is $22.33, with a market capitalization of $1.6B. The stock has returned +2.62% over the past 12 months and +10.78% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Innoviva, Inc. stock is Buy, with an average 12-month price target of $40.00. In fiscal year 2025, Innoviva, Inc. reported revenue of $425.1M and net income of $271.2M. For detailed data — including Innoviva, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Innoviva, Inc. (INVA) stock price is $22.33. The stock is traded on NASDAQ under the ticker symbol INVA. The 52-week range is $16.52 – $25.15.